The 44 compounds mentioned in our review in Table 1, Table 2 and Table 3 are not agonists of DR5, but they can produce anti-prostate-cancer effects by promoting the expression of DR5. The gene discussed is TNFRSF10B; the disease is Familial prostate cancer.